Roche signs definitive share purchase agreement with long-term partner TIB.
The Pharma Data
SEPTEMBER 8, 2021
TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days. About TIB Molbiol.
Let's personalize your content